Related Experiment Video
Updated: Nov 5, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Response to crizotinib in a patient with MET-amplified hepatocellular carcinoma
Qinglian Chen1,2,3, Chunfeng Xie1,2,3, Kunliang Feng1,2,3
1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Aims:
Molecular profiling of hepatocellular carcinoma (HCC) has helped identify actionable genomic alterations that could guide therapeutic decision-making and clinical trial enrollment. However, in clinical practice, next-generation sequencing (NGS) is not extensively used in routine clinical care to identify patients with HCC who are likely to benefit from genome-directed targeted therapies.
Methods:
Here, we describe the case of a 66-year-old man with advanced HCC. After rapid progression on transarterial chemoembolization, the tissue sample obtained from biopsy was subjected to NGS to verify whether precision therapy was an option.
Results:
Our analysis revealed high MET amplification. The patient received crizotinib (250 mg, bid) and showed a remarkable response.
Conclusions:
Our case report suggests NGS could help identify patients with high MET amplification in HCC who were likely to benefit from MET inhibitors; moreover, this requires further investigation in clinical trials.
Insights
Next-generation sequencing (NGS) identified MET amplification in advanced hepatocellular carcinoma (HCC). Targeted therapy with crizotinib led to a significant patient response, highlighting NGS
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Molecular profiling of hepatocellular carcinoma (HCC) identifies actionable genomic alterations.
- Next-generation sequencing (NGS) is underutilized in routine HCC care for guiding targeted therapies.
Observation:
- A 66-year-old man with advanced HCC experienced rapid progression on standard treatment.
- NGS analysis of tumor biopsy was performed to assess suitability for precision therapy.
Findings:
- High MET amplification was detected in the patient's HCC.
- The patient demonstrated a remarkable response to crizotinib, a MET inhibitor.
Implications:
- NGS can identify HCC patients with MET amplification who may benefit from MET inhibitors.
- Further clinical trials are warranted to validate these findings and explore MET-targeted therapies in HCC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers